Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 7/2012

01-07-2012 | Review Article

Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions

Authors: Dr Jeffrey R. Curtis, Monika M. Safford

Published in: Drugs & Aging | Issue 7/2012

Login to get access

Abstract

Osteoporosis is a highly prevalent chronic disease in the US and worldwide. The most serious consequence of this disorder is fractures, which have a serious negative impact on quality of life and are often the trigger for accelerated deterioration, ultimately ending in death. Despite the availability of effective preventive treatments, osteoporosis is frequently underdiagnosed and/or undertreated, particularly among the elderly, who are also at greatest risk. In addition, the presence of co-morbid medical conditions may be both a barrier to osteoporosis care and a risk factor for falls; thus individuals with multiple co-morbid conditions may be a particularly high-risk group.
The management of osteoporosis involves improving bone health via adequate nutrition, calcium and vitamin D supplements, and fall prevention strategies. Although these measures are important in the management of all patients, most elderly patients are likely to need additional pharmacological therapy to adequately reduce their fracture risk. Several pharmacological treatments have been shown to significantly reduce the risk of fracture, including bisphosphonates (e.g. alendronate, risedronate, ibandronate, zoledronic acid), denosumab, raloxifene, calcitonin and teriparatide.
Despite recent advances in osteoporosis care, additional action is urgently needed to improve the quality of life of osteoporotic patients in general and of elderly patients in particular, since fracture outcomes are typically poorer in older than in younger patients. This article reviews the current status of osteoporosis management, emphasizing the need to improve osteoporosis care, with a particular focus on the US, by the use of quality-improvement measures and incentives, which might result in an increased awareness and improved treatment for this debilitating disease.
Literature
1.
Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003; 921: 1–164.
2.
3.
Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007; 22: 465–75.PubMedCrossRef
4.
Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25–146.PubMedCrossRef
5.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46–215.PubMedCrossRef
6.
7.
Curtis JR, Arora T, Matthews RS, et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 2010; 11: 584–91.PubMedCentralPubMedCrossRef
8.
Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008; 22: 765–85.PubMedCrossRef
9.
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761–7.PubMedCrossRef
10.
Hallberg I, Rosenqvist AM, Kartous L, et al. Health-related quality of life after osteoporotic fractures. Osteoporos Int 2004; 15: 834–41.PubMedCrossRef
11.
Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006; 38: 694–700.PubMedCrossRef
12.
Dawson-Hughes B, Tosteson AN, Melton 3rd LJ, et al., National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19: 449–58.PubMedCrossRef
13.
14.
15.
Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19: 1431–44.PubMedCrossRef
16.
Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 2008; 121: 406–18.PubMedCentralPubMedCrossRef
17.
Peppone LJ, Hebl S, Purnell JQ, et al. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int 2010; 21: 1133–49.PubMedCentralPubMedCrossRef
18.
Katz S, Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) 2010; 6: 506–17.
19.
VanderWalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 2011; 61: 139–56.PubMedCrossRef
20.
21.
Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 716–24.PubMedCrossRef
22.
23.
Gillespie L, Handoll H. Prevention of falls and fall-related injuries in older people. Inj Prev 2009; 15: 354–5.PubMedCrossRef
24.
Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92: 1415–23.PubMedCrossRef
25.
Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009; 2: CD000227.PubMed
26.
Latham NK, Anderson CS, Lee A, et al. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the frailty interventions trial in elderly subjects (FITNESS). J Am Geriatr Soc 2003; 51: 291–9.PubMedCrossRef
27.
Porthouse J, Cockayne S, King C, et al. Randomized controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1–6.CrossRef
28.
Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomized evaluation of calcium or vitamin D, RECORD): a randomized placebocontrolled trial. Lancet 2005; 365: 1621–8.PubMedCrossRef
29.
Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and risk of fractures. N Engl J Med 2006; 354: 669–83.PubMedCrossRef
30.
Law M, Withers H, Morris J, et al. Vitamin D supplementation and the prevention of fractures and falls: results of a randomized trial in elderly people in residential accommodation. Age Ageing 2006; 35: 482–6.PubMedCrossRef
31.
Lyons RA, Johansen A, Brophy S, et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int 2007; 18: 811–8.PubMedCrossRef
32.
Annweiler C, Montero-Odasso M, Schott AM, et al. Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects. J Neuroeng Rehabil 2010; 7: 50.PubMedCentralPubMedCrossRef
33.
Ip TP, Leung J, Kung AW. Management of osteoporosis in patients hospitalized for hip fractures. Osteoporos Int 2010; 21 Suppl. 4:S605–14.PubMedCrossRef
34.
Gates S, Fisher JD, Cooke MW, et al. Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and metaanalysis. BMJ 2008; 336: 130–3.PubMedCentralPubMedCrossRef
35.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–41.PubMedCrossRef
36.
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82.PubMedCrossRef
37.
Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9: 461–8.PubMedCrossRef
38.
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52.PubMedCrossRef
39.
Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91.
40.
McClung M, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group]. N Engl J Med 2001; 344: 333–40.PubMedCrossRef
41.
Chesnut 3rd CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241–9.CrossRef
42.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–22.PubMedCrossRef
43.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799–809.PubMedCrossRef
44.
Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000; 109: 267–76.
45.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–45.PubMedCrossRef
46.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–41.PubMedCrossRef
47.
Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459–68.PubMedCrossRef
48.
Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816–22.PubMedCrossRef
49.
Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006; 21: 1113–20.PubMedCrossRef
50.
51.
Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153–61.PubMedCrossRef
52.
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–65.PubMedCrossRef
53.
Boonen S, Black DM, Colón-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010; 58: 292–9.PubMedCentralPubMedCrossRef
54.
Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52: 1832–9.PubMedCrossRef
55.
Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782–9.PubMedCrossRef
56.
Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008; 3: 279–97.PubMedCentralPubMed
57.
Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD001155.
58.
Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD004523.
59.
Abrahamsen M, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171: 998–1004.PubMed
60.
Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19: 1039–45.PubMedCrossRef
61.
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927–38.PubMedCrossRef
62.
Mellström DD, Sörensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462–8.PubMedCrossRef
63.
Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011; 71:791–814.PubMedCrossRef
64.
Armamento-Villareal R, Napoli N, Panwar V, et al. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006; 355: 2048–50.PubMedCrossRef
65.
Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007; 30: 590–7.PubMedCrossRef
66.
Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304–6.PubMedCrossRef
67.
Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15: 613–20.PubMedCrossRef
68.
Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93: 2948–52.PubMedCrossRef
69.
Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009; 85: 37–44.PubMedCrossRef
70.
Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89: 349–53.PubMedCrossRef
71.
Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20: 1353–62.PubMedCrossRef
72.
Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24: 1095–102.PubMedCrossRef
73.
Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267–94.PubMedCrossRef
74.
Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010; 304: 1480–4.PubMedCrossRef
75.
Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009; 360: 89–90.PubMedCrossRef
76.
Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009; 360: 1789.PubMedCrossRef
77.
Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009; 360: 1789–90.PubMedCrossRef
78.
79.
Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009; 8: 96–110.CrossRef
80.
Actonel® (risedronate sodium) tablets: US prescribing information. Rockaway (NJ): Warner Chilcott (US), LLC, 2011.
81.
82.
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–37.PubMedCrossRef
83.
Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999–2005. J Bone Miner Res 2008; 23: 1061–7.PubMedCentralPubMedCrossRef
84.
85.
86.
National Committee for Quality Assurance. The state of health care quality 2007. Washington, DC: National Committee for Quality Assurance, 2007 [online]. Available from URL: http://​www.​ncqa.​org [Accessed 2011 Aug 10].
87.
Curtis JR, Kim Y, Bryant T, et al. Osteoporosis in the home health care setting: a window of opportunity? Arthritis Rheum 2006; 55: 971–5.PubMedCrossRef
88.
Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999; 9: 151–7.PubMedCrossRef
89.
Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 136: 742–6.PubMedCrossRef
90.
Parikh S, Avorn J, Solomon DH. Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc 2009; 57: 327–34.PubMedCrossRef
91.
Colón-Emeric C, Casebeer L, Saag K, et al. Barriers to providing osteoporosis care in skilled nursing facilities: perceptions of medical directors and directors of nursing. J Am Med Dir Assoc 2005; 6 (3 Suppl.): S61–6.PubMedCrossRef
92.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998; 351: 1451–67.CrossRef
93.
Messerli F, Pinto L, Tang SS, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy: a meta-analysis. Am J Cardiol 2008; 101: 319–25.PubMedCrossRef
94.
95.
Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140–3.PubMedCrossRef
96.
Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20: 433–9.PubMedCrossRef
97.
98.
Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730–7.PubMedCentralPubMedCrossRef
99.
Adachi JD, Lyles KW, Colón-Emeric CS, et al. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int. Epub 2011 Jan 20. doi: 10.1007/s00198-010-1514–9.
100.
Tosi LL, Gliklich R, Kannan K, et al. The American Orthopaedic Association’s “own the bone” initiative to prevent secondary fractures. J Bone Joint Surg Am 2008; 90: 163–73.PubMedCrossRef
101.
Feldstein A, Elmer PJ, Smith DH, et al. Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 2006; 54: 450–7.PubMedCrossRef
102.
103.
Lewiecki EM, Baim S, Siris ES. Osteoporosis care at risk in the United States. Osteoporos Int 2008; 19: 1505–9.PubMedCrossRef
Metadata
Title
Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions
Authors
Dr Jeffrey R. Curtis
Monika M. Safford
Publication date
01-07-2012
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2012
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11599620-000000000-00000

Other articles of this Issue 7/2012

Drugs & Aging 7/2012 Go to the issue

Original Research Article

Hospitalization as a Turning Point for Sleep Medication Use in Older Adults

Therapy In Practice

Management of Seizures following a Stroke

Review Article

Antimuscarinic Treatment in Overactive Bladder

Original Research Article

Pharmacist-Led Medication Review to Identify Medication-Related Problems in Older People Referred to an Aged Care Assessment Team

Original Research Article

Content Validity and Inter-Rater Reliability of an Instrument to Characterize Unintentional Medication Discrepancies

Current Opinion

Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits